Yes Dr, ichm is now with TSOI but he supports RGBP and his RGBP patents which RGBP owns! LoL!
From June which is after May by the way LoL!
Beside the successful study and the FDA Clearance for
HemaXellerate
Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
Fat stem cell based product to treat bone marrow that has been damaged
Bone marrow damage occurs from radiation, chemo, or chronic conditions
HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow
?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)
Here is what else I see company announcement so Far!
Fully reporting and trades publicly under the symbol: RGBP
• Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing
• Currently 2 Investigational New Drug applications (IND) filed with the FDA
• Three products in preclinical development based on the newly discovered cancer stem cell gene target
Telomeres & Genomic Integrity
Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
Telomeres are protective structures at the ends of chromosomes that enable cell divisions
Telomere attrition is involved in aging, cancer and genetic mutations
We are developing drugs that modulate telomere maintenance
In pre-clinical development for indications of solid cancers and acute leukemia
Small Molecules Targeting Cancer and Autoimmunity
Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
Objective is to identify small molecules that can activate and inhibit NR2F6
?Currently in pre-clinical development
Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
Additional indications include solid tumors, acute leukemia and GVHD
dCellVax
Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
10 advanced breast cancer patients
Efficacy endpoints at 6 and 12 months
Establishment of safety will allow for rapid expansion of patient numbers
Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program
DiffronC
Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
siRNA silencing of our newly discovered cancer stem cell target gene
Silencing using DiffronC induces differentiation of cancer cells
Initial indication is treatment of myelodysplastic syndrome
Other indications include solid tumors and acute leukemia
News 
Market Data 
Discover 
